NEW YORK (GenomeWeb News) – CML HealthCare and XDx jointly announced today that CML has licensed exclusive rights to market XDx's AlloMap test initially in Ontario, Canada but with an option to extend the rights across the country.

Mississauga, Ontario-based CML, a publicly held diagnostic services provider, expects to begin offering the test later this summer. Financial and other terms of the alliance were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.